Analysts Offer Predictions for CYCC Q1 Earnings

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Research analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cyclacel Pharmaceuticals in a research note issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff forecasts that the biotechnology company will post earnings of ($0.29) per share for the quarter. Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million.

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research report on Thursday, November 7th. They set a “sell” rating on the stock.

Cyclacel Pharmaceuticals Stock Up 9.8 %

NASDAQ CYCC opened at $0.45 on Thursday. The company has a 50-day simple moving average of $0.88 and a 200-day simple moving average of $1.44. Cyclacel Pharmaceuticals has a one year low of $0.37 and a one year high of $7.84.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 23.58% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.